Instead, understanding the effects of differential expression of PD-L1 in specific immune and tumor cells in the TME may reveal mechanisms of the PD-1/PD-L1 axis that could be exploited to better predict response to ICI therapy. The gene discussed is PDCD1; the disease is neoplasm.